Published in Biochemistry on July 26, 2005
Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol (2013) 1.03
Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int (2011) 0.91
Design of a superior cytokine antagonist for topical ophthalmic use. Proc Natl Acad Sci U S A (2013) 0.84
Study on the effect of solution conditions on heat induced-aggregation of human alpha interferon. Iran J Pharm Res (2014) 0.82
Orthogonal high-throughput thermal scanning method for rank ordering protein formulations. AAPS PharmSciTech (2013) 0.81
Structural and thermodynamic effects of ANS binding to human interleukin-1 receptor antagonist. Protein Sci (2008) 0.80
Multistep aggregation pathway of human interleukin-1 receptor antagonist: kinetic, structural, and morphological characterization. Biophys J (2009) 0.79
Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex. J Pharm Sci (2006) 1.60
Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis (2007) 1.49
Differences in binding and effector functions between classes of TNF antagonists. Cytokine (2009) 1.46
High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci (2010) 1.19
Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem (2012) 1.09
Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition. Biochemistry (2010) 1.05
Peptide cysteine thiyl radicals abstract hydrogen atoms from surrounding amino acids: the photolysis of a cystine containing model peptide. J Phys Chem B (2008) 1.04
Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. J Pharm Sci (2009) 1.00
Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv Drug Deliv Rev (2003) 0.97
Reversible intramolecular hydrogen transfer between protein cysteine thiyl radicals and alpha C-H bonds in insulin: control of selectivity by secondary structure. J Phys Chem B (2008) 0.97
Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. J Pharm Sci (2009) 0.96
Investigation of degradation processes in IgG1 monoclonal antibodies by limited proteolysis coupled with weak cation-exchange HPLC. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.96
Mechanism for benzyl alcohol-induced aggregation of recombinant human interleukin-1 receptor antagonist in aqueous solution. J Pharm Sci (2004) 0.95
Rapid intrachain binding of histidine-26 and histidine-33 to heme in unfolded ferrocytochrome C. Biochemistry (2002) 0.95
The use of native cation-exchange chromatography to study aggregation and phase separation of monoclonal antibodies. Protein Sci (2010) 0.94
Exposure of a monoclonal antibody, IgG1, to UV-light leads to protein dithiohemiacetal and thioether cross-links: a role for thiyl radicals? Chem Res Toxicol (2010) 0.91
Photolysis of an intrachain peptide disulfide bond: primary and secondary processes, formation of H2S, and hydrogen transfer reactions. J Phys Chem B (2010) 0.91
Reversible hydrogen transfer between cysteine thiyl radical and glycine and alanine in model peptides: covalent H/D exchange, radical-radical reactions, and L- to D-Ala conversion. J Phys Chem B (2010) 0.90
Reversible hydrogen transfer reactions of cysteine thiyl radicals in peptides: the conversion of cysteine into dehydroalanine and alanine, and of alanine into dehydroalanine. J Phys Chem B (2011) 0.89
Biophysical characterization of structural properties and folding of interleukin-1 receptor antagonist. J Mol Biol (2007) 0.88
Secondary structures of proteins adsorbed onto aluminum hydroxide: infrared spectroscopic analysis of proteins from low solution concentrations. Anal Biochem (2006) 0.87
Comparison of high-throughput biophysical methods to identify stabilizing excipients for a model IgG2 monoclonal antibody: conformational stability and kinetic aggregation measurements. J Pharm Sci (2012) 0.87
Temperature dependence of benzyl alcohol- and 8-anilinonaphthalene-1-sulfonate-induced aggregation of recombinant human interleukin-1 receptor antagonist. Biochemistry (2006) 0.86
The triplet-state lifetime of indole derivatives in aqueous solution. Photochem Photobiol (2004) 0.85
The effect of sucrose hydrolysis on the stability of protein therapeutics during accelerated formulation studies. J Pharm Sci (2009) 0.85
Phase separation in solutions of monoclonal antibodies and the effect of human serum albumin. Proc Natl Acad Sci U S A (2011) 0.85
Phase transitions in human IgG solutions. J Chem Phys (2013) 0.85
Characterization of site-specific glycation during process development of a human therapeutic monoclonal antibody. J Pharm Sci (2011) 0.85
Detection and quantitation of IgG 1 hinge aspartate isomerization: a rapid degradation in stressed stability studies. Anal Chem (2009) 0.85
Entanglement model of antibody viscosity. J Phys Chem B (2014) 0.85
Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis. J Pharm Sci (2010) 0.84
Physical and biophysical effects of polysorbate 20 and 80 on darbepoetin alfa. J Pharm Sci (2009) 0.84
Native-state solubility and transfer free energy as predictive tools for selecting excipients to include in protein formulation development studies. J Pharm Sci (2012) 0.84
Nondenaturing size-exclusion chromatography-mass spectrometry to measure stress-induced aggregation in a complex mixture of monoclonal antibodies. Anal Chem (2013) 0.83
Effect of sugar molecules on the viscosity of high concentration monoclonal antibody solutions. Pharm Res (2011) 0.83
Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics. J Pharm Sci (2013) 0.82
Conformational equilibration time of unfolded protein chains and the folding speed limit. Biochemistry (2007) 0.82
Proapoptotic activity of cytochrome c in living cells: effect of K72 substitutions and species differences. Mol Cell Biochem (2008) 0.82
The photolysis of disulfide bonds in IgG1 and IgG2 leads to selective intramolecular hydrogen transfer reactions of cysteine Thiyl radicals, probed by covalent H/D exchange and RPLC-MS/MS analysis. Pharm Res (2013) 0.82
Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations. J Pharm Sci (2005) 0.82
Effect of pH and light on aggregation and conformation of an IgG1 mAb. Mol Pharm (2012) 0.81
Quantitative evaluation of colloidal stability of antibody solutions using PEG-induced liquid-liquid phase separation. Mol Pharm (2014) 0.81
Viscoelastic characterization of high concentration antibody formulations using quartz crystal microbalance with dissipation monitoring. J Pharm Sci (2009) 0.81
Characterization of a unique IgG1 mAb CEX profile by limited Lys-C proteolysis/CEX separation coupled with mass spectrometry and structural analysis. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.80
Construction and purification of the murine p75-murine IgG1 fusion protein. J Investig Dermatol Symp Proc (2007) 0.80
A quantitative kinetic study of polysorbate autoxidation: the role of unsaturated fatty acid ester substituents. Pharm Res (2009) 0.79
Potent activity of soluble B7RP-1-Fc in therapy of murine tumors in syngeneic hosts. Int J Cancer (2003) 0.79
Free fatty acid particles in protein formulations, part 1: microspectroscopic identification. J Pharm Sci (2014) 0.79
Kinetic folding mechanism of erythropoietin. Biophys J (2009) 0.79
Light-induced aggregation of type I soluble tumor necrosis factor receptor. J Pharm Sci (2009) 0.79
Light-induced conversion of Trp to Gly and Gly hydroperoxide in IgG1. Mol Pharm (2013) 0.78
Pharmacodynamic effects of the murine p75-Fc fusion protein in mice. J Investig Dermatol Symp Proc (2007) 0.78
Middle-down fragmentation for the identification and quantitation of site-specific methionine oxidation in an IgG1 molecule. J Pharm Sci (2010) 0.77
Effect of benzyl alcohol on recombinant human interleukin-1 receptor antagonist structure and hydrogen-deuterium exchange. J Pharm Sci (2011) 0.77
Linking the solution viscosity of an IgG2 monoclonal antibody to its structure as a function of pH and temperature. J Pharm Sci (2013) 0.77
Remediating agitation-induced antibody aggregation by eradicating exposed hydrophobic motifs. MAbs (2014) 0.76
Characterization of an oncolytic herpes simplex virus drug candidate. J Pharm Sci (2014) 0.76
Fluorogenic tagging methodology applied to characterize oxidized tyrosine and phenylalanine in an immunoglobulin monoclonal antibody. Pharm Res (2013) 0.76
Relationship between native-state solubility and non-native aggregation of recombinant human granulocyte colony stimulating factor: practical implications for protein therapeutic development. Mol Pharm (2014) 0.76
Characterization of 64Cu-DOTA-conatumumab: a PET tracer for in vivo imaging of death receptor 5. J Nucl Med (2011) 0.76
Understanding the relevance of local conformational stability and dynamics to the aggregation propensity of an IgG1 and IgG2 monoclonal antibodies. Protein Sci (2013) 0.75
Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material. J Pharm Sci (2014) 0.75
A deoxygenation system for measuring protein phosphorescence. Anal Biochem (2004) 0.75
High-performance liquid chromatography-based protease detection at the picogram level. Anal Biochem (2004) 0.75
Oxidation of free L-histidine by tert-Butylhydroperoxide. Pharm Res (2010) 0.75
Designed experiments with binary responses. J Pharm Sci (2011) 0.75